This study is testing a new oral medication called PLB1004 for people with non-small cell lung cancer (NSCLC). This medication is for those whose cancer has specific changes (mutations) in a gene called EGFR. Researchers want to understand how safe PLB1004 is and how your body handles it. To join, you must be at least 18 years old, have recovered from previous cancer treatments or major surgery, and have a confirmed EGFR mutation in your cancer. The study is currently enrolling patients, with a plan for 81 participants in total. The main goal is to track any side effects of PLB1004 for up to two years.

Study design

This is a Phase 1, multi-center study where both you and your doctors will know which treatment you are receiving (open-label). It will involve a small number of participants, ranging from 21 to 42 in the first part, to find the best dose.

What's involved

You will take PLB1004 by mouth as the only treatment. The study will involve different groups (cohorts) to find the right dose.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for up to two years after starting the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.